Sarah Spencer
Investor Relations Contact bij VOR BIOPHARMA INC.
Profiel
Sarah Spencer is currently the Head-Investor & Media at Vor Biopharma, Inc. She previously worked as a Media Relations Contact at GSK Plc and as the Vice President-Corporate Communications at Astellas Gene Therapies, Inc. from 2019 to 2021.
Ms. Spencer obtained an undergraduate degree from the State University of New York at Buffalo.
Actieve functies van Sarah Spencer
| Bedrijven | Functie | Begin |
|---|---|---|
| VOR BIOPHARMA INC. | Investor Relations Contact | - |
Eerdere bekende functies van Sarah Spencer
| Bedrijven | Functie | Einde |
|---|---|---|
| AUDENTES THERAPEUTICS, INC. | Public Communications Contact | 01-04-2021 |
| GSK PLC | Public Communications Contact | - |
Opleiding van Sarah Spencer
| State University of New York at Buffalo | Undergraduate Degree |
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
Eerstegraads connecties
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
| Beursgenoteerde bedrijven | 2 |
|---|---|
| GSK PLC | Health Technology |
| VOR BIOPHARMA INC. | Health Technology |
| Bedrijven in privébezit | 1 |
|---|---|
Astellas Gene Therapies, Inc.
 Astellas Gene Therapies, Inc. BiotechnologyHealth Technology Astellas Gene Therapies, Inc. is a biotechnology company, which engages in the development and commercialization of gene therapy products for patients with serious and rare diseases caused by single gene defects. The company was founded by Matthew R. Patterson and Thomas J. Schuetz on November 13, 2012 and is headquartered in San Francisco, CA. | Health Technology |
